Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$86.53 USD
+0.55 (0.64%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $86.49 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Axsome Therapeutics, Inc. [AXSM]
Reports for Purchase
Showing records 1 - 20 ( 184 total )
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solriamfetol Patent Litigation Settlement Reached; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Continued Sales Momentum; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solriamfetol ENGAGE Phase 3 Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AXS-12 SYMPHONY Phase 3 Trial Yields Positive Data; Raising PT to $190
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solriamfetol PARADIGM Phase 3 Trial Starts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Path to Profitability; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department